Specific Aim 1 (primary for RCT): To evaluate effectiveness of STAR-C.
Hypothesis 1a: In-Person STAR-C will lead to a greater decrease in everyday cognitive complaints (C4) compared to wait-list control.
Hypothesis 1b: Tele STAR-C will lead to a greater decrease in everyday cognitive complaints (C4) compared to wait-list control.
Specific Aim 2 (secondary): To evaluate maintenance of treatment effects using a practice based evidence approach.
Question 2a: What proportion of in-person STAR-C treatment effects (C4 and GAS) will be maintained at the 3-month follow-up?
Question 2b: What proportion of telehealth STAR-C treatment effects (C4 and GAS) will be maintained at the 3-month follow-up?
Specific Aim 3 (exploratory): To explore factors associated with heterogeneity in treatment response.
Question 3a: What factors prevented participants from achieving a ≥2-point improvement on the C4?
Question 3b: What factors prevented participants from maintaining ≥2-point improvement on the C4?
Question 3c: What factors prevented participants from achieving ≥2 out of 3 targets using GAS?
Question 3d: What factors contributed to participants maintaining or exceeding targets (GAS) at the 3-month follow-up?
Specific Aim 4 (implementation): Use stakeholder input (to include clinicians, administrators, and patients) from capacity assessment and after-action review to generate an implementation package for clinics interested in STAR-C.
Question 4: For what proportion of patients will clinicians rate STAR-C as acceptable, appropriate, and feasible (AIM/IAM/FIM)?